Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Update on International Expansion

2 Feb 2017 07:00

RNS Number : 8077V
Crimson Tide PLC
02 February 2017
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Update on International Expansion

 

Crimson Tide (AIM: TIDE), provider of mpro5, Smart Mobility as a Service, is pleased to update the market on its progress with international expansion. As announced in the Company's Trading Update on 14 December 2016, we have begun to invest in international expansion following the success of our partnership in Ireland. Similar to our model in Ireland, the strategic emphasis is on initiating growth through collaborative partnerships with known third parties, where there is a clear demand for mpro5, thereby creating considerable potential with limited risk. As such, the following developments are being put in place:

 

· Western Europe - Erik-Jan Smulders has been appointed to expand the Company's sales footprint in the region. Previously with BlackBerry, Erik has significant experience in growing businesses across Europe, Middle East and Asia ('EMEA') in both the Small Medium Business ("SMB") and Enterprise markets, both through channel and direct sales.

 

· UAE - The Company has signed an agreement with BCB (British Centres for Business) in Dubai, to take advantage of its Incubator Programme. BCB will focus on the setup of Crimson Tide's Dubai office and UAE business through the introduction to potential partners. Additionally, their role is to act as facilitator by introducing mpro5 to key emerging verticals in this region; namely Facilities Management and Health.

 

· United States - Crimson Tide will shortly join RX360, the trade organisation which includes 18 of the world's top 20 pharmaceutical companies and many of their global suppliers. This follows introductions from RX360 to APEC Business Advisory Council in the US, as well as other pharma businesses where mpro5 is currently in the pilot/early implementation stages. RX360's mission is to promote patient safety by improving the integrity of the Healthcare supply chain; an area where mpro5 has an important role to play. As a result, Crimson Tide is likely to open a small representative office in the coming months.

 

· Australia - The Company has entered into a Memorandum of Understanding with Mobilise IT in Melbourne. This partnership will see Mobilise IT include mpro5 in its business strategy, as well as offer first line support. In return, Crimson Tide will include Mobilise IT's mconcierge service in its offerings & support across Europe. This collaboration offers Crimson Tide the ability to reach prospects and clients across the Asia-Pacific region.

Laurence D'Arcy, previously Managing Director of the Company's business in Ireland has taken responsibility for international expansion.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "Demand for our mpro5 service has grown from international sources and we have multiple, early stage opportunities already in some of these markets. Rather than open overseas presences with highly speculative plans at great cost, we are being much more tactical, taking advantage of specific opportunities, with people we know and trust. We hope to see some tangible results from investments in the second half of the year. With considered increases in overheads we are placing the Company in a strong position for much higher growth in future years."

For further information please contact:

 

Crimson Tide plc

Barrie Whipp / Steve Goodwin

 

01892 542 444

WH Ireland

James Joyce / James Bavister

 

020 7220 1666

Alma PR

Josh Royston / Robyn McConnachie

O77 8090 1979 / 075 4070 6191

 

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDEAPAFEDKXEFF
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.